echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NMPA approves China's first querceton single anti-biosimilar.

    NMPA approves China's first querceton single anti-biosimilar.

    • Last Update: 2020-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fuhong Hanxuan announced that its self-developed quercexal mono-biosimilar HLX02 has been approved for listing by the State Drug Administration (NMPA).
    July 27, ZERX02 also received approval from the European Commission (EC), making HLX02 the first "Chinese national" mono-anti-biosimilar to be approved in Europe.
    the common name of
    HLX02 is curt bead monoantin (150 mg/bottle, no preservatives) and can be used to treat HER2-positive early breast cancer, HER2-positive metastatic breast cancer, and HER2-positive metastatic stomach cancer.
    during the development of HLX02, Fu Honghanjun strictly followed the biosimilar guidelines of the NMPA and the European Medicines Agency (EMA) and made several head-to-head comparisons between HLX02 and Hessetin.
    preclinical studies, Phase 1 clinical studies, and Global Multi-Center Phase 3 clinical studies show that HLX02 is highly similar in quality, safety and efficacy to Hersheytin.
    Photo Source: Mr. Zhang Wenjie, President of Fuhong Hanxuan's official website, said: "HLX02 is the second product approved by Fuhong Hanxuan in China after Lytoxi single anti-counterfeiting drugs, and the first product to be approved by the international drug regulatory agency."
    hope that HLX02 will benefit china's HER2-positive breast and stomach cancer patients.
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.